San Diego-based mostly Viking Therapeutics marked itself as a serious competitor during the weight loss drug current market in February following revealing promising facts from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented like a weekly injection As well as in March